
    
      PROTOCOL OUTLINE: H5.001CBCFTR, an adenovirus vector containing the cystic fibrosis
      transmembrane conductance regulator gene, is administered endobronchially.

      Cohort of 2 patients receive 1 of 6 H5.001CBCFTR concentrations. There is no intrapatient
      dose escalation.
    
  